Structure Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
GPCR$21.41+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| · · JUNE 30, · · DECEMBER 31, · | |||||||
| · 2024 · 2023 | |||||||
| Assets | | | | | | | |
| Current assets: · · | |||||||
| Cash and cash equivalents | | $381,627 | | $129,792 | | ||
| Short-term investments | | 545,492 | | 337,531 | | ||
| Prepaid expenses and other current assets | | 10,502 | | 6,285 | | ||
| Total current assets | | 937,621 | | 473,608 | | ||
| Property and equipment, net | | 3,315 | | 3,228 | | ||
| Operating right-of-use assets | | 4,267 | | 5,136 | | ||
| Other non-current assets | | 1,826 | | 45 | | ||
| Total assets | | $947,029 | | $482,017 | | ||
| Liabilities and shareholders’ equity | | | | ||||
| Current liabilities: | | | | ||||
| Accounts payable | | $2,209 | | $4,742 | | ||
| Accrued expenses and other current liabilities | | 18,821 | | 18,558 | | ||
| Operating lease liabilities, current portion | | 1,629 | | 1,440 | | ||
| Total current liabilities | | 22,659 | | 24,740 | | ||
| Operating lease liabilities, net of current portion | | | 3,045 | | | 4,013 | |
| Other non-current liabilities | | | 293 | | | 298 | |
| Total liabilities | | 25,997 | | 29,051 | | ||
| Commitments and contingencies (Note 5) | | | | ||||
| Shareholders’ equity: | | | | | |||
| Undesignated shares – $0.0001 par value; 100,000 shares authorized as of June 30, 2024 and December 31, 2023 | | | — | | | — | |
| Ordinary shares – $0.0001 par value; 500,000 shares authorized as of June 30, 2024 and December 31, 2023; 171,589 and 139,220 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | | 17 | | 14 | | ||
| Additional paid-in capital | | 1,180,144 | | 659,003 | | ||
| Accumulated other comprehensive (loss) income | | (487) | | 521 | | ||
| Accumulated deficit | | (258,642) | | (206,572) | | ||
| Total shareholders’ equity | | 921,032 | | 452,966 | | ||
| Total liabilities and shareholders’ equity | | $947,029 | | $482,017 | | ||
| | | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.